Systemic therapy of atopic dermatitis in children and adults

Current Problems in Dermatology

Volumn 41, Issue , 2011, Pages 156-164

  Simon, Dagmar ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; ALITRETINOIN; AZATHIOPRINE; CYCLOSPORIN; GAMMA INTERFERON; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERLEUKIN 4; MEPOLIZUMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMALIZUMAB; PREDNISONE; RITUXIMAB;

APOPTOSIS; ARTICLE; ATOPIC DERMATITIS; B LYMPHOCYTE; BEDTIME DOSAGE; CELL PROLIFERATION; CUSHING SYNDROME; DIABETES MELLITUS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; GASTROINTESTINAL DISEASE; GENE EXPRESSION; GLAUCOMA; GROWTH RETARDATION; HAND ECZEMA; HERPES ZOSTER; HUMAN; HYPERTENSION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY DISEASE; LEUKOPENIA; LIVER DYSFUNCTION; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PRURITUS; PUVA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN ATROPHY; SKIN CANCER; SKIN INFLAMMATION; STAPHYLOCOCCUS INFECTION; STOMACH ULCER; SYSTEMIC THERAPY; T LYMPHOCYTE; THROMBOCYTOPENIC PURPURA;

ADRENAL CORTEX HORMONES; ADULT; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CHILD; CYCLOSPORINE; DERMATITIS, ATOPIC; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA, RECOMBINANT; METHOTREXATE; MYCOPHENOLIC ACID; TRETINOIN;

EID: 84925953297     PISSN: 14215721     EISSN: 16622944     Source Type: Book Series    
DOI: 10.1159/000323309     Document Type: Article

References (58)

1. Galli E, Chini L, Moschese V, Paone F, Menichelli A, Fraioli G, Rossi P: Methylprednisolone bolus: a novel therapy for severe atopic dermatitis. Acta Paediatr 1994;83:315-317. (Pubitemid 24121141)
2. La Rosa M, Musarra I, Ranno C, Maiello N, Negri L, Del Giudice MM: A randomized, double-blind, placebo-controlled crossover trial of systemic flunisolode in the treatment of children with severe atopic dermatitis. Curr Ther Res 1995;56:720-726.
3. Akdis CA, Akdis M, Bieber T, Bindslev-Jensen C, Boguniewicz M, Eigenmann P, Hamid Q, Kapp A, Leung DY, Lipozencic J, Luger TA, Muraro A, Novak N, Platts-Mills TA, Rosenwasser L, Scheynius A, Simons FE, Spergel J, Turjanmaa K, Wahn U, Weidinger S, Werfel T, Zuberbier T, European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology: Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol 2006;118: 152-169. (Pubitemid 43946480)
4. Aylett SE, Atherton DJ, Preece MA: The treatment of difficult atopic dermatitis in childhood with oral beclomethasone dipropionate. Acta Derm Venereol Suppl (Stockh) 1992;176:123-125.
5. Liu J: FK506 and cyclosporin, molecular probes for studying intracellular signal transduction. Immunol Today 1993;14:290-295. (Pubitemid 23186993)
6. Hoare C, Li Wan Po A, Williams H: Systematic review of treatments for atopic eczema. Health Technol Assess 2000;4:1-191.
7. Schmitt J, Schmitt N, Meurer M: Cyclosporin in the treatment of patients with atopic eczema -a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2007;21:606-619. (Pubitemid 46916758)
8. Czech W, Bröutigam M, Weidinger G, Schöf E: A body-weight-independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life. J Am Acad Dermatol 2000;42:653-659. (Pubitemid 30479891)
9. Harper JI, Ahmed I, Barclay G, Lacour M, Hoeger P, Cork MJ, Finlay AY, Wilson NJ, Graham-Brown RA, Sowden JM, Beard AL, Sumner MJ, Berth-Jones J: Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol 2000;142:52-58. (Pubitemid 30074470)
10. Granlund H, Erkko P, Sinisalo M, Reitamo S: Cyclosporin in atopic dermatitis: time to relapse and effect of intermittent therapy. Br J Dermatol 1995;132:106-112.
11. Haw S, Shin MK, Haw CR: The efficacy and safety of long-term oral cyclosporine treatment for patients with atopic dermatitis. Ann Dermatol 2010; 22:9-15.
12. Hoang-Xuan T, Prisant O, Hannouche D, Robin H: Systemic cyclosporine A in severe atopic keratoconjunctivitis. Ophthalmology 1997;104:1300-1305. (Pubitemid 28048727)
13. Mrowietz U, Klein CE, Reich K, Rosenbach T, Ruzicka T, Sebastian M, Werfel T: Cyclosporine therapy in dermatology. J Dtsch Dermatol Ges 2009; 7:474-479.
14. Buckley DA, Baldwin P, Rogers S. The use of azathioprine in severe adult atopic eczema. J Eur Acad Dermatol Venereol 1998;11:137-140. (Pubitemid 28445034)
15. Kuanprasert N, Herbert O, Barnetson RS: Clinical improvement and significant reduction of total serum IgE in patients suffering from severe atopic dermatitis treated with oral azathioprine. Austral J Dermatol 2002;43:125-127. (Pubitemid 34533965)
16. Hughes R, Collins P, Rogers S: Further experience of using azathioprine in the treatment of severe atopic dermatitis. Clin Exp Dermatol 2008;33: 710-711.
17. Berth-Jones J, Takwale A, Tan E, Barclay G, Agarwal S, Ahmed I, Hotchkiss K, Graham-Brown RA: Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol 2002;147:324-330.
18. Hon KL, Ching GK, Leung TF, Chow CM, Lee KK, Ng PC: Efficacy and tolerability at 3 and 6 months following use of azathioprine for recalcitrant atopic dermatitis in children and young adults. J Dermatol Treat 2009;20:141-145.
19. Meggitt SJ, Gray JC, Reynolds NJ: Azathioprine dosed by thiopurine methyltransferase activity for moderateto-severe atopic eczema: a double-blind, randomised controlled trial. Lancet 2006;367:839-846. (Pubitemid 43363371)
20. Murphy LA, Atherton DJ: Azathioprine as a treatment for severe atopic eczema in children with a partial thiopurine methyl transferase (TPMT) deficiency. Pediatr Dermatol 2003;20:531-534. (Pubitemid 38021322)
21. Grundmann-Kollmann M, Korting HC, Behrens S, Leiter U, Krähn G, Kaufmann R, Peter RU, Kerscher M: Successful treatment of severe refractory atopic dermatitis with mycophenolate mofetil. Br J Dermatol 1999;141:175-176. (Pubitemid 29333728)
22. Grundmann-Kollmann M, Podda M, Ochsendorf F, Boehncke WH, Kaufmann R, Zollner TM: Mycophenolate mofetil is effective in the treatment of atopic dermatitis. Arch Dermatol 2001;137:870-873. (Pubitemid 32641646)
23. Murray ML, Cohen JB: Mycophenolate mofetil therapy for moderate to severe atopic dermatitis. Clin Exp Dermatol 2007;32:23-27. (Pubitemid 46006360)
24. Benez A, Fierlbeck G: Successful long-term treatment of severe atopic dermatitis with mycophenolate mofetil. Br J Dermatol 2001;144:638-639. (Pubitemid 32232035)
25. Heller M, Shin HT, Orlow SJ, Schaffer JV: Mycophenolate mofetil for severe childhood atopic dermatitis: experience in 14 patients. Br J Dermatol 2007;157:127-132. (Pubitemid 46934265)
26. Neuber K, Schwartz I, Itschert G, Dieck AT: Treatment of atopic eczema with oral mycophenolate mofetil. Br J Dermatol 2000;143:385-391. (Pubitemid 30650410)
27. Hantash B, Fiorentino D: Liver enzyme abnormalities in patients with atopic dermatitis treated with mycophenolate mofetil. Arch Dermatol 2006; 142: 109-110. (Pubitemid 43107373)
28. Weatherhead SC, Wahie S, Reynolds NJ, Meggitt SJ: An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema. Br J Dermatol 2007;156:346-351. (Pubitemid 46095964)
29. Goujon C, Bérard F, Dahel K, Guillot I, Hennino A, Nosbaum A, Saad N, Nicolas JF: Methotrexate for the treatment of adult atopic dermatitis. Eur J Dermatol 2006;16:155-158.
30. Lyakhovitsky A, Barzilai A, Heyman R, Baum S, Amichai B, Solomon M, Shpiro D, Trau H: Lowdose methotrexate treatment for moderate-tosevere atopic dermatitis in adults. J Eur Acad Dermatol Venereol 2010;24:43-49.
31. Ruzicka T, Lynde CW, Jemec GB, Diepgen T, Berth-Jones J, Coenraads PJ, Kaszuba A, Bissonnette R, Varjonen E, HollöP, Cambazard F, Lahfa M, Elsner P, Nyberg F, Svensson A, Brown TC, Harsch M, Maares J: Efficacy and safety of oral alitretinoin (9-cis-retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol 2008;158:808-817. (Pubitemid 351415754)
32. Grahovac M, Molin S, Prinz JC, Ruzicka T, Wollenberg A: Treatment of atopic eczema with oral alitretinoin. Br J Dermatol. 2010;162:217-218.
33. Kimata H: High dose gammaglobulin treatment for atopic dermatitis. Arch Dis Child 1994;70:335-336. (Pubitemid 24174751)
34. Jolles S, Sewell C, Webster D, Ryan A, Heelan B, Waite A, Rustin M: Adjunctive high-dose intravenous immunoglobulin treatment for resistant atopic dermatitis: efficacy and effects on intracellular cytokine levels and CD4 counts. Acta Derm Venereol 2003;83:433-437. (Pubitemid 37475784)
35. Jolles S, Hughes J, Rustin M: The treatment of atopic dermatitis with adjunctive high-dose intravenous immunoglobulin: a report of three patients and review of the literature. Br J Dermatol 2000;142: 551-554. (Pubitemid 30159088)
36. Huang JL, Lee WY, Chen LC, Kuo ML, Hsieh KH: Changes of serum levels of interleukin-2, intercellular adhesion molecule-1, endothelial leukocyte adhesion molecule-1 and Th1 and Th2 cell in severe atopic dermatitis after intravenous immunoglobulin therapy. Ann Allergy Asthma Immunol 2000;84: 345-352.
37. Wakim M, Alazard M, Yajima A, Speights D, Saxon A, Stiehm ER: High dose intravenous immunoglobulin in atopic dermatitis and hyper-IgE syndrome. Ann Allergy Asthma Immunol 1998;81:153-158. (Pubitemid 28413031)
38. Paul C, Lahfa M, Bachelez H, Chevret S, Dubertret L: A randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis. Br J Dermatol 2002;147: 518-522. (Pubitemid 35015288)
39. Boguniewicz M, Jaffe HS, Izu A, Sullivan MJ, York D, Geha RS, Leung DY: Recombinant gamma interferon in treatment of patients with atopic dermatitis and elevated IgE levels. Am J Med 1990;88: 365-370. (Pubitemid 20147271)
40. Hanifin JM, Schneider LC, Leung DY, Ellis CN, Jaffe HS, Izu AE, Bucalo LR, Hirabayashi SE, Tofte SJ, Cantu-Gonzales G, et al: Recombinant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol 1993;28:189-197. (Pubitemid 23053704)
41. Stevens SR, Hanifin JM, Hamilton T, Tofte SJ, Cooper KD: Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels. Arch Dermatol 1998;134:799-804. (Pubitemid 28350182)
42. Schneider LC, Baz Z, Zarcone C, Zurakowski D: Long-term therapy with recombinant interferongamma (rIFN-gamma) for atopic dermatitis. Ann Allergy Asthma Immunol 1998;80:263-268. (Pubitemid 28145315)
43. Simon D, Wittwer J, Kostylina G, Buettiker U, Simon HU, Yawalkar N: Alefacept (lymphocyte function-associated molecule 3/IgG fusion protein) treatment for atopic eczema. J Allergy Clin Immunol 2008;122:423-424.
44. Moul DK, Routhouska SB, Robinson MR, Korman NJ: Alefacept for moderate to severe atopic dermatitis: a pilot study in adults. J Am Acad Dermatol 2008;58:984-989.
45. Takiguchi R, Tofte S, Simpson B, Harper E, Blauvelt A, Hanifin J, Simpson E: Efalizumab for severe atopic dermatitis: a pilot study in adults. J Am Acad Dermatol 2007;56:222-227. (Pubitemid 46074243)
46. Ibler K, Dam TN, Gniadecki R, Kragballe K, Jemec GB, Agner T: Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases. J Eur Acad Dermatol Venereol 2010;24:837-839.
47. Simon D, Höli S, Kostylina G, Yawalkar N, Simon HU: Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 2008;121: 122-128.
48. SediváA, KayserováJ, VernerováE, Poloucková A, Capková S Spodie;ekocá R, Bartùnková J: Anti-CD20 (rituximab) treatment for atopic eczema. J Allergy Clin Immunol 2008;121:1515-1516.
49. Oldhoff JM, Darsow U, Werfel T, Katzer K, Wulf A, Laifaoui J, Hijnen DJ, Plöz S, Knol EF, Kapp A, Bruijnzeel-Koomen CA, Ring J, de Bruin-Weller MS: Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy 2005;60:693-696. (Pubitemid 40562479)
50. Belloni B, Ziai M, Lim A, Lemercier B, Sbornik M, Weidinger S, Andres C, Schnopp C, Ring J, Hein R, Ollert M, Mempel M: Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 2007;120:1223-1225. (Pubitemid 350047479)
51. Sheinkopf LE, Rafi AW, Do LT, Katz RM, Klaustermeyer WB: Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc 2008;29:530-537.
52. Vigo PG, Girgis KR, Pfuetze BL, Critchlow ME, Fisher J, Hussain I: Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol 2006;55:168-170. (Pubitemid 43867028)
53. Incorvaia C, Pravettoni C, Mauro M, Yacoub MR, Tarantini F, Riario-Sforza GG: Effectiveness of omalizumab in a patient with severe asthma and atopic dermatitis. Monaldi Arch Chest Dis 2008;69: 78-80.
54. Jacobi A, Antoni C, Manger B, Schuler G, Hertl M: Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 2005;52: 522-526.
55. Cassano N, Loconsole F, Coviello C, Vena GA: Infliximab in recalcitrant severe atopic eczema associated with contact allergy. Int J Immunopathol Pharmacol 2006;19:237-240.
56. Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Röert J, Audring H, Kary S, Burmester GR, Sterry W, Worm M: Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol 2007;156:486-491.
57. Vestergaard C, Deleuran M, Kragballe K: Two cases of atopic dermatitis-like conditions induced in psoriasis patients treated with infliximab. J Eur Acad Dermatol Venereol 2007;21:1272-1274. (Pubitemid 47423430)
58. Davaine AC, Saraux A, Prigent S, Kupfer-Bessaguet I, Roswag D, Plantin P, Schoenlaub P, Talarmin F, Zagnoli A, Misery L: Cutaneous events during treatment of chronic inflammatory joint disorders with anti-tumour necrosis factor alpha: a crosssectional study. J Eur Acad Dermatol Venereol 2008;22:1471-1477.